Patents by Inventor Michael E. Houston
Michael E. Houston has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11938191Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: GrantFiled: May 1, 2020Date of Patent: March 26, 2024Assignee: GENEVANT SCIENCES GMBHInventors: Sean D. Monahan, Michael S. Declue, Pierrot Harvie, Russell N. Johnson, Amber E. Paschal, Mary G. Prieve, Debashish Roy, Charbel Diab, Michael E. Houston, Jr., Anna Galperin, Maher Qabar
-
Patent number: 11684584Abstract: Disclosed are branched PEG molecules, including branched PEG-lipids and branched-PEG proteins, as well as related compositions and methods for making branched PEG molecules. Also disclosed are related compositions, systems, and methods for in vivo delivery of therapeutic and diagnostic agents.Type: GrantFiled: December 29, 2017Date of Patent: June 27, 2023Assignee: Genevant Sciences GmbHInventors: Debashish Roy, Jean-Rene E. Ella-Menye, Sean D. Monahan, Pierrot Harvie, Anna Galperin, Michael E. Houston, Mary G. Prieve
-
Publication number: 20230038687Abstract: Disclosed are methods for delivering a therapeutic or diagnostic agent to the cytosol of a cell in a subject. The disclosed methods generally include administering to the subject an effective amount of a lipid nanoparticle comprising the therapeutic or diagnostic agent and an effective amount of a membrane-destabilizing polymer. Also disclosed are related compositions and delivery systems.Type: ApplicationFiled: January 7, 2022Publication date: February 9, 2023Inventors: Mary G. PRIEVE, Michael E. HOUSTON, JR., Pierrot HARVIE, Sean D. MONAHAN
-
Patent number: 11219634Abstract: Disclosed are methods for delivering a therapeutic or diagnostic agent to the cytosol of a cell in a subject. The disclosed methods generally include administering to the subject an effective amount of a lipid nanoparticle comprising the therapeutic or diagnostic agent and an effective amount of a membrane-destabilizing polymer. Also disclosed are related compositions and delivery systems.Type: GrantFiled: January 21, 2016Date of Patent: January 11, 2022Assignee: Genevant Sciences GmbHInventors: Mary G. Prieve, Michael E. Houston, Jr., Pierrot Harvie, Sean D. Monahan
-
Publication number: 20210023235Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: ApplicationFiled: May 1, 2020Publication date: January 28, 2021Applicant: GENEVANT SCIENCES GMBHInventors: Sean D. MONAHAN, Michael S. DeCLUE, Pierrot HARVIE, Russell N. JOHNSON, Amber E. PASCHAL, Mary G. PRIEVE, Debashish ROY, Charbel DIAB, Michael E. HOUSTON, JR., Anna GALPERIN, Maher QABAR
-
Patent number: 10660970Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: GrantFiled: August 16, 2019Date of Patent: May 26, 2020Assignee: Genevant Sciences GmbHInventors: Sean D. Monahan, Michael S. DeClue, Pierrot Harvie, Russell N. Johnson, Amber E. Paschal, Mary G. Prieve, Debashish Roy, Charbel Diab, Michael E. Houston, Jr., Anna Galperin, Maher Qabar
-
Patent number: 10646582Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: GrantFiled: November 30, 2017Date of Patent: May 12, 2020Assignee: Genevant Sciences GmbHInventors: Sean D. Monahan, Michael S. DeClue, Pierrot Harvie, Russell N. Johnson, Amber E. Paschal, Mary G. Prieve, Debashish Roy, Charbel Diab, Michael E. Houston, Jr., Anna Galperin, Maher Qabar
-
Publication number: 20200078313Abstract: Disclosed are branched PEG molecules, including branched PEG-lipids and branched-PEG proteins, as well as related compositions and methods for making branched PEG molecules. Also disclosed are related compositions, systems, and methods for in vivo delivery of therapeutic and diagnostic agents.Type: ApplicationFiled: December 29, 2017Publication date: March 12, 2020Applicant: Genevant Sciences GmbH.Inventors: Debashish ROY, Jean-Rene E. ELLA-MENYE, Sean D. MONAHAN, Pierrot HARVIE, Anna GALPERIN, Michael E. HOUSTON, JR., Mary G. PRIEVE
-
Publication number: 20190388551Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: ApplicationFiled: August 16, 2019Publication date: December 26, 2019Applicant: GENEVANT SCIENCES GMBHInventors: Sean D. MONAHAN, Michael S. DeCLUE, Pierrot HARVIE, Russell N. JOHNSON, Amber E. PASCHAL, Mary G. PRIEVE, Debashish ROY, Charbel DIAB, Michael E. HOUSTON, Anna GALPERIN, Maher QABAR
-
Publication number: 20180353607Abstract: This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.Type: ApplicationFiled: August 14, 2017Publication date: December 13, 2018Inventors: Steven C. Quay, Michael E. Houston, Jr., Pierrot Harvie, Roger C. Adami, Renata Fam, Mary Prieve, Kathy Fosnaugh, Shaguna Seth
-
Publication number: 20180243433Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: ApplicationFiled: November 30, 2017Publication date: August 30, 2018Inventors: Sean D. Monahan, Michael S. DeClue, Pierrot Harvie, Russell N. Johnson, Amber E. Paschal, Mary G. Prieve, Debashish Roy, Charbel Diab, Michael E. Houston, JR., Anna Galperin, Maher Qabar
-
Publication number: 20180221402Abstract: Disclosed are methods for delivering a therapeutic or diagnostic agent to the cytosol of a cell in a subject. The disclosed methods generally include administering to the subject an effective amount of a lipid nanoparticle comprising the therapeutic or diagnostic agent and an effective amount of a membrane-destabilizing polymer. Also disclosed are related compositions and delivery systems.Type: ApplicationFiled: January 21, 2016Publication date: August 9, 2018Inventors: Mary G. PRIEVE, Michael E. HOUSTON, JR., Pierrot HARVIE, Sean D. MONAHAN
-
Patent number: 10023863Abstract: This invention provides single-stranded and multi-stranded compounds that are useful in various therapeutic modalities to regulate the expression of nucleic acid molecules in a cell. A range of compounds is provided, each containing one or more conformationally restricted nucleomonomers (CRN). In addition, compounds can contain one or more conformationally restricted nucleomonomers and one or more hydroxymethyl substituted nucleomonomers (unlocked nucleomonomers, UNA).Type: GrantFiled: February 17, 2015Date of Patent: July 17, 2018Assignee: Marina Biotech, Inc.Inventors: Michael V. Templin, Narendra K. Vaish, Kathy L. Fosnaugh, Shaguna Seth, Michael E. Houston, Jr.
-
Patent number: 9867885Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: GrantFiled: July 30, 2014Date of Patent: January 16, 2018Assignee: PhaseRx, Inc.Inventors: Sean D Monahan, Michael S Declue, Pierrot Harvie, Russell N Johnson, Amber E Paschal, Mary G Prieve, Debashish Roy, Charbel Diab, Michael E Houston, Jr., Anna Galperin, Maher Qabar
-
Patent number: 9821067Abstract: Lipopeptide compounds having a central peptide HHHHHKHHHKKKHKHKKK (SEQ ID NO:15) and a lipophilic group attached to each terminus of the peptide, and salts thereof. The lipopeptides are useful for forming pharmaceutical compositions for delivery of nucleic acid agents, such as siRNA and mdRNA agents, as well as in methods for treating the signs and symptoms of disease.Type: GrantFiled: November 16, 2015Date of Patent: November 21, 2017Assignee: Marina Biotech, Inc.Inventors: Roger C. Adami, Michael E. Houston, Jr., Rachel E. Johns
-
Patent number: 9751909Abstract: Processes for synthesis of conformationally restricted nucleomonomers (CRN) by ozonolysis or oxidation of a 2?-vinyl substituted nucleoside precursor with protected 3?-hydroxyl, 4?-hydroxymethyl and 5?-hydroxyl positions. The CRN nucleomonomers can be used to prepare nucleic acid compounds. CRN nucleomonomers for nucleic acid compounds can be prepared in high yields and in multi-gram scale. The nucleic acid compounds can be of various regulatory classes such as antisense RNA for therapeutic modalities useful for treating or preventing diseases or disorders by up- or down-regulating the expression of genes and other nucleic acid based regulatory systems in a cell.Type: GrantFiled: September 7, 2012Date of Patent: September 5, 2017Assignee: Marina Biotech, Inc.Inventors: Tracy J. Matray, Iwona M. Maciagiewicz, Michael E. Houston, Jr.
-
Patent number: 9731016Abstract: This disclosure provides a range of tyrosine amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.Type: GrantFiled: April 3, 2016Date of Patent: August 15, 2017Assignee: Marina Biotech, Inc.Inventors: Steven C. Quay, Michael E. Houston, Jr., Pierrot Harvie, Roger C. Adami, Renata Fam, Mary Prieve, Kathy Fosnaugh, Shaguna Seth
-
Publication number: 20170216227Abstract: Activity-generating delivery molecules comprising the structure R3—(C?O)-Xaa-NH—R4 wherein Xaa is any D- or L-amino acid residue with a non-hydrogen, substituted or unsubstituted side chain, R3—(C?O)— and —NH—R4 are independently a long chain group, each long chain group containing one or more carbon-carbon double bonds, and salts, compositions and methods of use thereof. The activity-generating delivery compounds and compositions are useful for generating activity of an active agent in a cell, tissue, or subject.Type: ApplicationFiled: April 13, 2017Publication date: August 3, 2017Inventors: Renata Fam, Roger C. Adami, Kathy L. Fosnaugh, Pierrot Harvie, Rachel E. Johns, Shaguna Seth, Michael E. Houston, JR., Michael V. Templin
-
Publication number: 20160215293Abstract: This invention provides oligomer structures for therapeutic agents, the oligomers composed of one or more UNA nucleomonomers, along with nucleic acid monomers. The UNA oligomers may be used as therapeutic agents for treating or preventing disease. The UNA oligomers can be capable of modulating or silencing gene expression, through RNA interference or other modalities, and may have an antisense strand and a sense strand.Type: ApplicationFiled: April 12, 2016Publication date: July 28, 2016Inventors: Michael V. Templin, Narendra K. Vaish, Barry A. Polisky, Michael E. Houston, JR.
-
Publication number: 20160206750Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: ApplicationFiled: July 30, 2014Publication date: July 21, 2016Inventors: Sean D MONAHAN, Michael S DECLUE, Pierrot HARVIE, Russell N JOHNSON, Amber E PASCHAL, Mary G PRIEVE, Debashish ROY, Charbel DIAB, Michael E HOUSTON, Jr., Anna GALPERIN, Maher QABAR